# The Absorption, Metabolism and Excretion of [14C]CM082 in Human

> **NCT04434326** · PHASE1 · COMPLETED · sponsor: **AnewPharma** · enrollment: 4 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** [14]CM082 suspension

## Key facts

- **NCT ID:** NCT04434326
- **Lead sponsor:** AnewPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-05
- **Primary completion:** 2021-10-22
- **Final completion:** 2021-10-22
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04434326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04434326, "The Absorption, Metabolism and Excretion of [14C]CM082 in Human". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04434326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*